APA (7th ed.) Citation

K, P., S, N., J, K., K, S., S, N., P, O., . . . P, P. (2026). Safety and Immunogenicity of a Locally Produced Inactivated NDV-HXP-S COVID-19 Vaccine (HXP-GPOVac) Compared with BNT162b2: A Phase II Randomized, Controlled, Double-Blind Noninferiority Trial in Thai Adults. Vaccines, 14(6), . https://doi.org/10.3390/vaccines14060481

Chicago Style (17th ed.) Citation

K, Prasert, et al. "Safety and Immunogenicity of a Locally Produced Inactivated NDV-HXP-S COVID-19 Vaccine (HXP-GPOVac) Compared with BNT162b2: A Phase II Randomized, Controlled, Double-Blind Noninferiority Trial in Thai Adults." Vaccines 14, no. 6 (2026). https://doi.org/10.3390/vaccines14060481.

MLA (9th ed.) Citation

K, Prasert, et al. "Safety and Immunogenicity of a Locally Produced Inactivated NDV-HXP-S COVID-19 Vaccine (HXP-GPOVac) Compared with BNT162b2: A Phase II Randomized, Controlled, Double-Blind Noninferiority Trial in Thai Adults." Vaccines, vol. 14, no. 6, 2026, https://doi.org/10.3390/vaccines14060481.